Axsome Therapeutics Inc

Key Account Manager I (Sao Paulo)

Brazil

Not SpecifiedCompensation
Mid-level (3 to 4 years)Experience Level
Full TimeJob Type
UnknownVisa
Biopharmaceutical, PharmaceuticalsIndustries

Requirements

The candidate must be based in Sao Paulo and possess a Bachelor's degree in a related business or scientific discipline. Required experience includes pharmaceutical/biotechnology sales or key account management with high-cost products, and hands-on experience interacting with third parties and patient organizations. Experience with specialty pharmacy distribution and patient access services is also necessary. Experience with rare diseases is desirable.

Responsibilities

The Key Account Manager will represent PTC's products to medical professionals within an assigned geographic region, building business partnerships with healthcare providers and staff. Responsibilities include increasing awareness through scientific information and education, developing and executing regional action plans to achieve sales goals, and understanding marketing plan objectives. The role involves creating consultative partnerships with customers, identifying key treatment centers, driving patient identification initiatives, and managing relationships with health authorities, key opinion leaders, patient organizations, and payors. The manager will also resolve product access and reimbursement issues, provide training on product use, communicate drug information and side effects to the Pharmacovigilance Department, and collaborate with internal teams to drive commercial business.

Skills

Pharmaceutical Sales
Relationship Building
Client Relations
Sales Strategy
Communication
Scientific Information
Territory Management
Business Development

Axsome Therapeutics Inc

Develops therapies for CNS disorders

About Axsome Therapeutics Inc

Axsome Therapeutics develops therapies for central nervous system (CNS) disorders, focusing on conditions like major depressive disorder, treatment-resistant depression, and Alzheimer's agitation. Their main product, AXS-05, is an oral medication that works by blocking NMDA receptors in the brain, which helps regulate mood. This drug has shown positive results in clinical trials and has received special FDA status to speed up its approval process. Unlike many competitors, Axsome emphasizes addressing unmet medical needs in CNS disorders and aims to improve patient outcomes through rigorous research and development. The company's goal is to bring effective treatments to market, enhancing the quality of life for patients suffering from these conditions.

New York City, New YorkHeadquarters
2012Year Founded
$430.7MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
201-500Employees

Benefits

Performance Bonus
Company Equity

Risks

Increased competition from companies like Compass Pathways in the CNS market.
Potential delays in AXS-07 launch amid growing market anticipation.
Departure of key personnel like Lori Englebert may impact strategic direction.

Differentiation

Axsome focuses on CNS disorders with limited current treatment options.
AXS-05, an NMDA receptor antagonist, targets major depressive disorder and treatment-resistant depression.
Axsome's balanced portfolio includes both clinical and research stage products.

Upsides

FDA's fast-tracking of CNS treatments could expedite Axsome's drug approvals.
Increased investment in CNS R&D drives innovation, benefiting Axsome's pipeline.
Growing personalized medicine trend offers Axsome opportunities for tailored therapies.

Land your dream remote job 3x faster with AI